Preclinical data with tasquinimod in MDS presented at ASH 2022 available on Active Biotech’s website
Lund, December 13, 2022 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that preclinical data on tasquinimod, a small molecule immunomodulator, in myelodysplastic syndrome (MDS), are now available on the company’s website. The data were presented at a poster presentation at the 64th American Society of Hematology Annual Meeting in New Orleans, Louisiana, December 10, 2022.
The poster, titled Targeting S100A9 in the Inflammatory Myelodysplastic Hematopoietic Niche Reprograms the Functional Properties of CD271+ Mesenchymal Stromal Cells was presented by Dr. Manja Wobus, University Hospital Dresden, Germany.
The presented data are the result of a collaboration between Active Biotech and an academic group in Dresden, Germany which aims at addressing the unmet medical need to treat MDS. The results show that a subpopulation of mesenchymal stromal cells, i.e. CD271+ MSC’s, is responsible for the diminished hematopoietic support. Tasquinimod modulates the function of these cells and thereby enhances their potential to support hematopoiesis in vitro.
“MDS is a heterogenous group of conditions, and the outcomes and treatment options depend on the subtype of the disease and prognostic risk groups. Next to stem cell transplantation, treatment options include immunosuppressant drugs and chemotherapy. There is an urgent need for novel treatment options that would impact the cause of the disease. The presented preclinical results suggest that tasquinimod has the potential to impact the diminished hematopoiesis which is a key pathogenic feature in MDS”, said Erik Vahtola, CMO at Active Biotech.
Information on the presentation:
P 1753. Targeting S100A9 in the Inflammatory Myelodysplastic Hematopoietic Niche Reprograms the Functional Properties of CD271+ Mesenchymal Stromal Cells. Poster session 636. Myelodysplastic Syndromes – Basic and Translational: Poster I. Dec 10, 2022, 5:30-7:30 PM. Ernest N. Morial Convention Center, Hall D. Dr. M. Wobus et al., University Hospital Dresden, Germany.
The poster presentation is now available on Active Biotech’s website. The abstract is also available on the ASH website.